And HR (Homologous Recombination) deficient ovarian cancer may be more sensitive to PD-1/PD-L1 inhibitors, and BRCA 1 and 2 mutations may leading HR deficient [30]. This evidence concerns the gene PDCD1 and ovarian carcinoma.